ScholarIQanswers from OpenAlex
Institut de Recherche en Cancérologie de Montpellier
InstitutionResearch output, impact & collaborations
Institut de Recherche en Cancérologie de Montpellier is a institution indexed in ScholarIQ from OpenAlex.
What is known about Institut de Recherche en Cancérologie de Montpellier?
ScholarIQrecord summary
Institut de Recherche en Cancérologie de Montpellier is a research organisation in Montpellier, FR. OpenAlex records 5,224 works and 510,275 citations for it. 1,122 researchers list it as their most recent affiliation.
How many works does Institut de Recherche en Cancérologie de Montpellier have?
ScholarIQindexed works
Institut de Recherche en Cancérologie de Montpellier has 5,224 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Institut de Recherche en Cancérologie de Montpellier have?
ScholarIQcitation count
Institut de Recherche en Cancérologie de Montpellier has 510,275 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Institut de Recherche en Cancérologie de Montpellier?
ScholarIQresearcher count
Institut de Recherche en Cancérologie de Montpellier has 1,122 researchers in the ScholarIQ index.
What is the average h-index at Institut de Recherche en Cancérologie de Montpellier?
ScholarIQavg h-index
Institut de Recherche en Cancérologie de Montpellier has an average h-index of 54.7 in OpenAlex.
What is the ROR of Institut de Recherche en Cancérologie de Montpellier?
ScholarIQror
The ROR for Institut de Recherche en Cancérologie de Montpellier is on the source record.
What is the OpenAlex record for Institut de Recherche en Cancérologie de Montpellier?
ScholarIQopenalex
The OpenAlex for Institut de Recherche en Cancérologie de Montpellier is on the source record.
Who are the most-cited researchers behind Institut de Recherche en Cancérologie de Montpellier?
ScholarIQtop researchers by citations
What are the most-cited papers on Institut de Recherche en Cancérologie de Montpellier?
ScholarIQmost cited works
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiß, Andrés Redondo, Hans Holger Fischer, William Jacot, Alison Conlin, Claudia Arce-Salinas, Irene Wapnir, Christian Jackisch, Michael P. DiGiovanna, Peter A. Fasching, John Crown, P Wülfing, Zhimin Shao, Elena Rota Caremoli, Haiyan Wu, Lisa H. Lam, David Tesarowski, Melanie C. Smitt, Hannah Douthwaite, Stina Mui Singel, Charles E. Geyer
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Eric Assénat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Dominique Farge, Corinne Frère, Jean M. Connors, Cihan Ay, Alok A. Khorana, Andrés J. Muñoz Martín, Benjamin Brenner, Ajay K. Kakkar, Hanadi Rafii, Susan Solymoss, Dialina Brilhante, Manuel Monréal, Henri Bounameaux, Ingrid Pabinger, James D. Douketis, Walter Ageno, Fernando Ajauro, Kamal R. Al-Aboudi, Thierry Alcindor, Thierry André, Pantep Angchaisuksiri, Darko Antić, Juan I. Arcelus, Eric Assénat, Kenneth A. Bauer, Ali Bazarbachii, Ilham Benzidia, Jan Beyer‐Westendorf, Viktoria Bitsadze, Dorit Blickstein, Mark Blostein, Isabel Bogalho, Barbara Bournet, Patricia Casais, Alain Carpentier, Gabriela Cesarman‐Maus, Joydeep Chakbrabartty, Hugo Clemente, J. Connault, Ludovic Doucet, C. Durant, Joseph Emmerich, Anna Falanga, Clemens Feistritzer, Carme Font, Charles W. Francis, Enrique Gallardo, Thomas Gary, Jean‐Christophe Gris, Cecilia Guillermo, A. Hij, Russel Hull, Takayuki Ikezoe, Luis Jara‐Palomares, Nigel S. Key, Jamilya Khrizroeva, Maral Koolian, Florian Länger, C. Le Hello, Ramón Lecumberri, Lai Heng Lee, Howard A. Liebman, Luisa Lopes Dos Santos, Duarte Machado, Isabelle Madelaine, А. D. Makatsariya, Mario Mandalà, Anthony Marayevas, Zora Marjanovic, Christine Marosi, Ellis Martin, Luis Meillón, E. Messas, António Moreira, Ahmet Muzaffer Demir, Arlette Ndour, Michel N'Guessan, Remedios Otero, Vanessa Pachón Olmos, Ana Pais, Florian Posch, Matthias Preusser, H. Riess, Marc Righini, Cynthia Rothschild, André Roussin, José Antonio Rueda-Camino, Pedro Ruiz‐Artacho, Sanjith Saseedharan, Ali Shamseddine, Gerald A. Soff, Hans Stricker, Vicky Tagalakis, Alì Taher, Toussaint Toutou, Javier Trujillo‐Santos, Stéphane Villiers, Raymond Wong, Norizaku Yamada
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Bruno Sangro, Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, Shukui Qin, Zhenggang Ren, Stephen L. Chan, Yasuaki Arai, Jeong Heo, Anh Mai, Jose Escobar, Yamil Alonso Lopez Chuken, Jung-Hwan Yoon, Won Young Tak, Valeriy V Breder, Tanita Suttichaimongkol, Mohamed Bouattour, Shi-Ming Lin, Jean-Marie Peron, Quang T Nguyen, Lünan Yan, Chang-Fang Chiu, Florinda A Santos, Anil Veluvolu, Satheesh Chiradoni Thungappa, Marco Matos, Magdalena Żotkiewicz, Stephanie I. Udoye, John F. Kurland, G. Cohen, Riccardo Lencioni, Kathia Cristina Abdalla, Manon Allaire, Gustavo R. Alves, Luís Carlos Moreira Antunes, Eric Assénat, Sérgio Jobim Azevedo, Rafael Barreto, Muhammad Shaalan Beg, Glaucio Bertollo, Jean‐Frédéric Blanc, Mohamed Bouattour, Rakesh Reddy Boya, Valery Breder, Jean–Pierre Bronowicki, Manoch Buranachokphaisan, Adam M. Burgoyne, Stephen L. Chan, Ting‐Tsung Chang, Yee Chao, Eric Chen, Xiaoming Chen, Chang-Fang Chiu, Minsig Choi, SUNGHEE CHOI, Natalie G. Coburn, Luis Contreras, Farshid Dayyani, Thomas Decaens, Arunee Dechaphunkul, Maria del Consuelo Diaz, Anouk Dev, Jamille Dutra, Melissa Eastgate, Jose Escobar, Bassam Estfan, Vittorio Ferrari, Anne-Claire Frin, Sandip Ganguly, Ranga Raman Ganta, Shanzhi Gu, Yabing Guo, Atsushi Hagihara, Jeong Heo, Chih‐Hung Hsu, Jimmy Hwang, Yoshitaka Inaba, Shikha Jain, D. Jonker, Shruti Kate, Shruti Kate, Naoya Kato, Tomokazu Kawaoka, Kwong‐Ming Kee, Seung Up Kim, Kiyohide Kioka, Hironori Koga, Masatoshi Kudo, Hidekatsu Kuroda, Phuong Uyen Le, Han-chu Lee, Joon Hyeok Lee, Teng-Yu Lee, Dongliang Li, Hailiang Li, Wei Li, Xiao Li, Cheng-Yao Lin, Shi-Ming Lin, Yamil Lopez
How much of the research on Institut de Recherche en Cancérologie de Montpellier is open access?
ScholarIQopen access share
86%OPEN ACCESS